Targanta Therapeutics Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 113

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $132M

  • Investors
  • 1

Targanta Therapeutics General Information

Description

Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Corporate Office
  • 222 Third Street
  • Suite 2300
  • Cambridge, MA 02142
  • United States
+1 (514) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Targanta Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 26-Feb-2009 $132M 00000 00000 Completed Clinical Trials - Phase 3
6. IPO 10-Oct-2007 000.00 00000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C3) 12-Feb-2007 000.00 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C2) 06-Jan-2005 0000 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series C1) 12-Mar-2002 000.00 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Dec-1999 $28.7M $30.3M 000.00 Completed Product Development
1. Seed Round 01-Dec-1997 $1.58M $1.58M 00.000 Completed Startup
To view Targanta Therapeutics’s complete valuation and funding history, request access »

Targanta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C3 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C2 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C1 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 245,000 $0.000100 8% $199.5 $199.5 1x $199.5 1.35%
Series A 20,000 $0.000100 $101.12 $101.12 1x $101.12 0.15%
To view Targanta Therapeutics’s complete cap table history, request access »

Targanta Therapeutics Executive Team (7)

Name Title Board Seat
Mark Leuchtenberger President & Chief Executive Officer
Daniel Char Vice President & General Counsel
You’re viewing 2 of 7 executive team members. Get the full list »

Targanta Therapeutics Board Members (1)

Name Representing Role Since
Randy Berholtz JD Self Board Member 000 0000
To view Targanta Therapeutics’s complete board members history, request access »

Targanta Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Targanta Therapeutics Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brookside Capital Venture Capital Minority 000 0000 000000 0
Fonds de solidarite FTQ PE/Buyout Minority 000 0000 000000 0
GrowthWorks Venture Capital Minority 000 0000 000000 0
InterMune Corporation 000 0000 000000 0
Le Centre CDP Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Targanta Therapeutics FAQs

  • When was Targanta Therapeutics founded?

    Targanta Therapeutics was founded in 1997.

  • Who is the CEO of Targanta Therapeutics?

    Mark Leuchtenberger is the CEO of Targanta Therapeutics.

  • Where is Targanta Therapeutics headquartered?

    Targanta Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Targanta Therapeutics?

    Targanta Therapeutics has 113 total employees.

  • What industry is Targanta Therapeutics in?

    Targanta Therapeutics’s primary industry is Pharmaceuticals.

  • Is Targanta Therapeutics a private or public company?

    Targanta Therapeutics is a Private company.

  • What is the current valuation of Targanta Therapeutics?

    The current valuation of Targanta Therapeutics is 00000.

  • What is Targanta Therapeutics’s current revenue?

    The current revenue for Targanta Therapeutics is 000000.

  • How much funding has Targanta Therapeutics raised over time?

    Targanta Therapeutics has raised $193M.

  • Who are Targanta Therapeutics’s investors?

    Brookside Capital, Fonds de solidarite FTQ, GrowthWorks, InterMune, and Le Centre CDP Capital are 5 of 12 investors who have invested in Targanta Therapeutics.

  • When was Targanta Therapeutics acquired?

    Targanta Therapeutics was acquired on 26-Feb-2009.

  • Who acquired Targanta Therapeutics?

    Targanta Therapeutics was acquired by The Medicines Company.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »